EYPT Logo

EyePoint Pharmaceuticals, Inc. (EYPT) 

NASDAQ
Market Cap
$613.92M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
2 of 775
Rank in Industry
2 of 432

Largest Insider Buys in Sector

EYPT Stock Price History Chart

EYPT Stock Performance

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the …

Insider Activity of EyePoint Pharmaceuticals, Inc.

Over the last 12 months, insiders at EyePoint Pharmaceuticals, Inc. have bought $89.68M and sold $120.66M worth of EyePoint Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at EyePoint Pharmaceuticals, Inc. have bought $29.98M and sold $43.05M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Cormorant Asset Management, LP (10 percent owner) — $1.34B. Zaderej Karen L. (director) — $199,500. ANDO GORAN (director) — $39,750.

The last purchase of 5,000 shares for transaction amount of $39,750 was made by ANDO GORAN (director) on 2024‑08‑21.

List of Insider Buy and Sell Transactions, EyePoint Pharmaceuticals, Inc.

2024-08-21Purchasedirector
5,000
0.0082%
$7.95$39,750-1.33%
2024-08-20Purchasedirector
2,567
0.0048%
$7.79$19,997+15.93%
2024-08-19Purchasedirector
12,500
0.0235%
$7.98$99,750+12.47%
2024-08-16Purchasedirector
3,173
0.0057%
$7.88$25,0030.00%
2024-07-12Saledirector
11,625
0.0274%
$10.06$116,9950.00%
2024-06-03Saledirector
11,625
0.0233%
$10.30$119,705-8.91%
2024-05-14Saledirector
11,625
0.0227%
$12.65$147,045-26.79%
2024-05-06Purchase10 percent owner
850,000
1.8064%
$11.86$10.08M-18.10%
2024-04-18Purchase10 percent owner
581,765
1.2029%
$18.03$10.49M-46.86%
2024-02-02SaleSVP & Chief Commercial Officer
209
0.0007%
$28.49$5,954-60.38%
2024-01-26SaleSVP & Chief Commercial Officer
26,017
0.0509%
$25.38$660,370-56.76%
2024-01-26SaleChief Medical Officer
49,325
0.0975%
$25.66$1.27M-56.76%
2024-01-25SaleSVP & Chief Commercial Officer
600
0.0012%
$25.00$15,000-53.73%
2024-01-25SaleChief Medical Officer
600
0.0012%
$25.00$15,000-53.73%
2024-01-24SaleExecutive Vice Chair
29,956
0.0887%
$24.98$748,250-51.69%
2024-01-24SaleSVP & Chief Commercial Officer
11,300
0.0335%
$25.01$282,621-51.69%
2024-01-24SaleChief Medical Officer
11,251
0.0334%
$25.01$281,415-51.69%
2024-01-23SaleExecutive Vice Chair
5,044
0.0144%
$24.97$125,950-53.48%
2024-01-23SaleSVP & Chief Commercial Officer
900
0.0026%
$25.00$22,500-53.48%
2024-01-23SaleChief Medical Officer
5,135
0.0146%
$25.00$128,375-53.48%

Insider Historical Profitability

6.64%
Cormorant Asset Management, LP10 percent owner
8325000
12.1976%
$9.0060
Lurker Nancydirector
97635
0.1431%
$9.0044<0.0001%
Zaderej Karen L.director
16500
0.0242%
$9.0010
ANDO GORANdirector
13150
0.0193%
$9.0010
DICICCO WENDY Fdirector
9967
0.0146%
$9.0010

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Cormorant Asset Management Lp$142.48M13.246.89M+14.16%+$17.67M6.64
Adage Capital Partners Gp L L C$98.31M9.134.76M+6.49%+$5.99M0.18
Suvretta Capital Management, LLC$77.8M7.233.76M-7.22%-$6.06M3.29
Franklin Templeton Investments$70.06M6.513.39M-26.97%-$25.87M0.02
BlackRock$57.61M5.352.79M+28.49%+$12.78M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.